Literature DB >> 21060039

Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology.

Mark G Kris1, Steven I Benowitz, Sylvia Adams, Lisa Diller, Patricia Ganz, Morton S Kahlenberg, Quynh-Thu Le, Maurie Markman, Greg A Masters, Lisa Newman, Jennifer C Obel, Andrew D Seidman, Sonali M Smith, Nicholas Vogelzang, Nicholas J Petrelli.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 21060039     DOI： 10.1200/JCO.2010.33.2742

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  24 in total

1.  Update in lung cancer and oncological disorders 2010.

Authors:  Balazs Halmos; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2011-08-01       Impact factor: 21.405

2.  Clinical trial design for rare cancers: why a less conventional route may be required.

Authors:  Katherine S Panageas
Journal:  Expert Rev Clin Pharmacol       Date:  2015       Impact factor: 5.045

3.  Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

Authors:  Daniel V T Catenacci; Les Henderson; Shu-Yuan Xiao; Premal Patel; Robert L Yauch; Priti Hegde; Jiping Zha; Ajay Pandita; Amy Peterson; Ravi Salgia
Journal:  Cancer Discov       Date:  2011-12       Impact factor: 39.397

4.  First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

Authors:  Vanja Vaccaro; Emilio Bria; Isabella Sperduti; Alain Gelibter; Luca Moscetti; Giovanni Mansueto; Enzo Maria Ruggeri; Teresa Gamucci; Francesco Cognetti; Michele Milella
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

5.  Cancer survival in Qidong between 1972 and 2011: A population-based analysis.

Authors:  Jian-Guo Chen; Jian Zhu; Yong-Hui Zhang; Yi-Xin Zhang; Deng-Fu Yao; Yong-Sheng Chen; Jian-Hua Lu; Lu-Lu Ding; Hai-Zhen Chen; Chao-Yong Zhu; Li-Ping Yang; Yuan-Rong Zhu; Fu-Lin Qiang
Journal:  Mol Clin Oncol       Date:  2017-05-03

6.  RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Authors:  Daniel V T Catenacci; Gustavo Cervantes; Soheil Yala; Erik A Nelson; Essam El-Hashani; Rajani Kanteti; Mohamed El Dinali; Rifat Hasina; Johannes Brägelmann; Tanguy Seiwert; Michele Sanicola; Les Henderson; Tatyana A Grushko; Olufunmilayo Olopade; Theodore Karrison; Yung-Jue Bang; Woo Ho Kim; Maria Tretiakova; Everett Vokes; David A Frank; Hedy L Kindler; Heather Huet; Ravi Salgia
Journal:  Cancer Biol Ther       Date:  2011-07-01       Impact factor: 4.742

7.  Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer.

Authors:  C L Attard; S Brown; K Alloul; M J Moore
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

8.  Impact of early palliative interventions on the outcomes of care for patients with non-small cell lung cancer.

Authors:  Carsten Nieder; Terje Tollåli; Ellinor Haukland; Anne Reigstad; Liv Randi Flatøy; Kirsten Engljähringer
Journal:  Support Care Cancer       Date:  2016-05-21       Impact factor: 3.603

9.  An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer.

Authors:  Mina Gaga; Charles A Powell; Dean E Schraufnagel; Nicolas Schönfeld; Klaus Rabe; Nicholas S Hill; Jean-Paul Sculier
Journal:  Am J Respir Crit Care Med       Date:  2013-08-15       Impact factor: 21.405

10.  Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia.

Authors:  Fabio Efficace; Gianantonio Rosti; Neil Aaronson; Francesco Cottone; Emanuele Angelucci; Stefano Molica; Marco Vignetti; Franco Mandelli; Michele Baccarani
Journal:  Haematologica       Date:  2013-11-15       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.